Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.
Krasniqi E, Ercolani C, Di Benedetto A, Di Lisa FS, Filomeno L, Arcuri T, Botti C, Pelle F, Cavicchi F, Cappelli S, Barba M, Pizzuti L, Maugeri-Saccà M, Moscetti L, Grassadonia A, Tinari N, Sanguineti G, Takanen S, Fragnito D, Terrenato I, Buglioni S, Perracchio L, Latorre A, De Maria R, Pallocca M, Ciliberto G, Giotta F, Vici P. Krasniqi E, et al. Among authors: ercolani c. Cancers (Basel). 2024 Jul 23;16(15):2628. doi: 10.3390/cancers16152628. Cancers (Basel). 2024. PMID: 39123356 Free PMC article.
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: ercolani c. Clin Cancer Res. 2011 Apr 1;17(7):2055-64. doi: 10.1158/1078-0432.CCR-10-1920. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307144
Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.
Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto A, Perracchio L, Melucci E, Iacobelli S, Mottolese M, Natali PG, Piantelli M; CINBO (Consorzio Interuniversitario Nazionale per Bio-Oncologia). Lattanzio R, et al. Among authors: ercolani c. Int J Cancer. 2013 Mar 1;132(5):1022-31. doi: 10.1002/ijc.27751. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22847294
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: ercolani c. Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472669
External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.
Terrenato I, Arena V, Pizzamiglio S, Pennacchia I, Perracchio L, Buglioni S, Ercolani C, Sperati F, Costarelli L, Bonanno E, Baldini D, Candia S, Crescenzi A, Dal Mas A, Di Cristofano C, Gomes V, Grillo LR, Pasquini P, Pericoli MN, Ramieri MT, Di Stefano D, Ruco L, Scarpino S, Vitolo D, d'Amati G, Paradiso A, Verderio P, Mottolese M. Terrenato I, et al. Among authors: ercolani c. J Exp Clin Cancer Res. 2013 Aug 21;32(1):58. doi: 10.1186/1756-9966-32-58. J Exp Clin Cancer Res. 2013. PMID: 23965490 Free PMC article.
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: ercolani c. Oncotarget. 2015 Dec 15;6(40):42773-80. doi: 10.18632/oncotarget.6001. Oncotarget. 2015. PMID: 26544894 Free PMC article.
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: ercolani c. J Exp Clin Cancer Res. 2016 Apr 2;35:62. doi: 10.1186/s13046-016-0338-7. J Exp Clin Cancer Res. 2016. PMID: 27039292 Free PMC article.
The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I, Shaaban AM, Sundara-Rajan S, Barba M, Speirs V, De Maria R, Maugeri-Saccà M. Di Benedetto A, et al. Among authors: ercolani c. Oncotarget. 2016 Jul 12;7(28):43188-43198. doi: 10.18632/oncotarget.9668. Oncotarget. 2016. PMID: 27248471 Free PMC article.
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Sundara-Rajan S, Humphries MP, Barba M, Speirs V, De Maria R, Maugeri-Saccà M. Di Benedetto A, et al. Among authors: ercolani c. Sci Rep. 2016 Oct 7;6:35121. doi: 10.1038/srep35121. Sci Rep. 2016. PMID: 27713571 Free PMC article.
Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.
Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Humphries MP, Sundara-Rajan S, Barba M, Speirs V, De Maria R, Maugeri-Saccà M. Di Benedetto A, et al. Among authors: ercolani c. J Cell Physiol. 2017 Aug;232(8):2246-2252. doi: 10.1002/jcp.25745. Epub 2017 Mar 3. J Cell Physiol. 2017. PMID: 27987320 Free article.
97 results